Background Recognizing the rapidly increasing interest and evidence in using metastasis-
directed radiotherapy (MDRT) for oligometastatic disease (OMD), ESTRO and ASTRO …

Introduction Improved outcome has been shown in patients with synchronous
oligometastatic (sOM) NSCLC when treated with radical intent. As a uniform definition of …

Background Lung cancer is the leading cause of cancer-related death worldwide, with non-
small cell lung cancer (NSCLC) accounting for most cases. While radiotherapy has …

Breast cancer remains the most common cause of cancer death among women. Despite its
considerable histological and molecular heterogeneity, those characteristics are not …

Background In contrast to other cancers, the concept of oligometastatic disease (OMD) has
not been investigated in bladder cancer (BC). Objective To develop an acceptable definition …

Oligometastatic (OMD) non‐small cell lung cancer (NSCLC) is a distinct but heterogeneous
entity. Current guidelines recommend systemic therapy and consolidation with local ablative …

Introduction This study analyzed all metastatic categories of the current TNM classification of
NSCLC to propose modifications of the M component in the next edition (ninth) of the …

Simple Summary The introduction of new therapies for non-small cell lung cancer (NSCLC)
has radically changed the point of view of thoracic surgeons, leading them to pay …

Background About 50% of non-small cell lung cancer (NSCLC) patients have metastatic
disease at initial diagnosis, which limits their treatment options and, consequently, the 5 …

Introduction Understanding prognosis, especially long-term outcome, in advanced nonsmall
cell lung cancer (NSCLC) is crucial to inform patients, guide treatment and plan supportive …